Oncology professionals from around the world will convene in Chicago to discuss the latest clinical cancer research impacting patient care at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Advances in therapies for rare and pediatric cancers, findings on disparities among patients with cancer, and new treatment options for patients with advanced breast, colorectal, and pancreatic cancers are among the topics that will be highlighted in the meeting’s official Press Program.
Patients with advanced non-small cell lung cancer without EGFR/ALK mutations who were treated with toripalimab plus first-line chemotherapy had better progression-free survival and overall survival compared to patients who received chemotherapy alone, according to research from the CHOICE-01 trial.
In patients with previously untreated metastatic or unresectable melanoma, the combination of nivolumab and relatlimab continued to demonstrate a progression-free survival benefit compared to nivolumab alone. The combination also demonstrated for the first time a higher overall response rate according to follow-up data from the RELATIVITY-047 trial. These data will be presented during an ASCO Plenary Series session taking place March 15, 2022, at 5:00 p.m. ET.
A scoring algorithm that incorporated 290 genetic variants for prostate cancer (PHS290) accurately identified people with high or low lifetime risks of developing metastatic prostate cancer or dying from the disease. Based on the risk scores, people with an African ancestry had the highest risk of developing metastatic prostate cancer and dying of the disease. The study will be presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, taking place February 17-19, 2022, in San Francisco, California.
Taking aspirin daily did not improve invasive disease-free survival (iDFS) in breast cancer patients, according to research being presented in the February 15, 2022 ASCO Plenary Series session.
Pancreatic cancer is a leading cause of cancer-related deaths; however, despite decades of research, limited progress has been made to improve survival. There are currently no FDA-approved treatment options for patients with pancreatic cancer that has progressed on first- and second-line chemotherapy. Sotorasib is active and well tolerated in patients with metastatic pancreatic cancer with a KRASG12C mutation, according to research being presented in the February 15, 2022, ASCO Plenary Series session.
Findings on a scoring algorithm for predicting the risk of developing metastatic or fatal prostate cancer will be highlighted in the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the nearly 600 abstracts that will be presented at the Symposium.
In patients with advanced gastrointestinal stromal tumors (GIST) that progressed on or were intolerant to imatinib, the efficacy of ripretinib was comparable to sunitinib. These findings from the INTRIGUE trial were presented during the January session of the American Society of Clinical Oncology (ASCO) Plenary Series.
Results from the randomized international phase III TOPAZ-1 trial showed that the checkpoint immunotherapy durvalumab (Imfinzi) plus chemotherapy drugs gemcitabine and cisplatin significantly improved overall survival in patients with advanced biliary tract cancer compared to patients who received a placebo plus the chemotherapy drugs. Biliary tract cancer is classified as a rare disease comprised primarily of bile duct and gallbladder cancers.
Results from the randomized international phase III HIMALAYA trial showed that a combination of durvalumab (Imfinzi) plus the experimental drug tremelimumab, both immunotherapies, significantly improved overall survival in patients with advanced, unresectable hepatocellular carcinoma, the most common type of liver cancer, compared to patients who received only sorafenib (Nexavar).
Findings on combination therapies with immunotherapy drugs for patients with biliary tract cancer and hepatocellular carcinoma will be highlighted in the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium’s official Press Program. Studies featured in the Press Program are among the more than 650 abstracts that will be presented at the Symposium.
Two studies from the inaugural ASCO Plenary Series session will highlight the latest practice-changing results in advanced melanoma and digital symptom monitoring. The studies will be presented in a live broadcast session on November 16, 2021, at 3:00 PM ET.
Interventions that paired community-based health workers with low-income and minority patients with cancer improved quality of life and may be a more effective and sustainable way to ensure equitable cancer care, according to a study to be presented as part of the 2021 ASCO Quality Care Symposium.
Ten noteworthy studies from the 2021 Quality Care Symposium explore topics such as financial burden of cancer treatment, fertility preservation, hidden disparities in breast cancer, and more. Leading cancer experts are available to comment on the on-demand and scheduled broadcast content from the 2021 Quality Care Symposium.
The majority (72.3%) of oral anticancer drugs received by patients required prior authorization, which was found to be associated with delayed time to drug receipt, according to a study to be presented at the 2021 ASCO Quality Care Symposium.